CVS rises after UBS upgrades on healthcare benefits recovery
Brokerage UBS upgrades healthcare conglomerate CVS Health CVS.N to "buy" from "neutral," raising PT to $79 from $67
New PT represents a ~13.2% upside to the stock's last close
Shares of CVS up 2.2% at $70.1 premarket
UBS says CVS has managed its Medicare Advantage plans well, giving the brokerage more confidence in its future performance
UBS believes CVS will reduce its debt by late 2026, allowing for more share buybacks and further earnings growth
UBS says it does not expect any major negative changes from drug pricing rules or its Star ratings in the near term
As of last close, CVS stock up 52.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
What is the CLARITY Act? 2026 Guide to US Crypto Regulation and Stablecoin Yield Rules

Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

Tradingkey






